Claroid Pharmaceuticals Limited - Due diligence report

A 360° intelligence report on Claroid Pharmaceuticals: trust score, financial health, credit view, compliance, directors, growth and distres…

2018-08-31 Daskroi, Gujarat Active Unlisted
Share
Connect MCP
CP Claroid Pharmaceuticals Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Claroid Pharmaceuticals — 360° Intelligence Report

Generated from MCA filings & public records
77/100
Trust Score
Low Risk

Claroid Pharmaceuticals is assessed as Low Risk with a Trust Score of 77/100. Claroid Pharmaceuticals is an active public limited indian non-government company incorporated in 2018, operating in the Pharma sector. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 13 Aug 2026 from the latest processed filings. Claroid Pharmaceuticals Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
77/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
83/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
75/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
30/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 75/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 1 open (33.83 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Hdfc Bank Limited1 48.0 cr
Compliance Score: 83/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 1 court forum(s).
  • 1 auditor resignation(s) filed - latest: D.G. PATEL & Co. on 2024-08-08.
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 30/100
NameDIN / PANDesignationAppointedTenureDIN status
RUSHIN BAIJUBHAI DESAI 01234567 Director 01/04/2018 6 yrs Approved
ARPANKUMAR PATEL 01234567 Director 01/04/2018 6 yrs Approved
GHANSHYAM ARJANBHAI PATEL 01234567 Director 01/04/2018 6 yrs Approved
SNEHALKUMAR HASMUKHLAL SONI 01234567 Director 01/04/2018 6 yrs Approved
SHAILESH ARJANBHAI PATEL 01234567 Director 01/04/2018 6 yrs Approved
Shashwat Yatishkumar Shah 01234567 Director 01/04/2018 6 yrs Approved
BAIJU BHUPENDRABHAI DESAI 01234567 Director 01/04/2018 6 yrs Approved
Baiju Bhupendrabhai Desai 01234567 Director 01/04/2018 6 yrs Approved
Chandrika Joshi 01234567 Director 01/04/2018 6 yrs Approved
Megha Parikh 01234567 Director 01/04/2018 6 yrs Approved
  • 10 directors on the board.
  • SHAILESH ARJANBHAI PATEL has DIN status "Deactivated due to non-filing of DIR-3 KYC".
  • 8 director exits in 3 years - high churn.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: RUSHIN BAIJUBHAI DESAI (Whole-time director) · SNEHALKUMAR HASMUKHLAL SONI (Whole-time director) · SHAILESH ARJANBHAI PATEL (Whole-time director) · BAIJU BHUPENDRABHAI DESAI (CFO)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 80 · Distress 80
Growth signals & trust indicators
Latest year revenue grew 1.42.
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
EPFO headcount growing - hiring signal.
Operating for 7 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
8 director exits within 2 years.
1 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence80/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment82/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 33.83 cr already registered.
  • Compliance record supports lending.
Investor view83/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 4 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 15 events
02 Aug 2025
Director appointed
Megha Parikh (Company Secretary)
31 Jul 2025
Last AGM held
Annual general meeting
30 Jul 2025
Director ceased
ARPANKUMAR PATEL
Director ceased
Shashwat Yatishkumar Shah
Director ceased
Chandrika Joshi
19 Jun 2025
Director appointed
Baiju Bhupendrabhai Desai (Cfo)
20 May 2025
Director appointed
BAIJU BHUPENDRABHAI DESAI (CFO)
19 May 2025
Director ceased
RUSHIN BAIJUBHAI DESAI
Director ceased
GHANSHYAM ARJANBHAI PATEL
Director ceased
SNEHALKUMAR HASMUKHLAL SONI
Director ceased
SHAILESH ARJANBHAI PATEL
Director ceased
BAIJU BHUPENDRABHAI DESAI
28 Apr 2025
Director appointed
ARPANKUMAR PATEL (Director)
Director appointed
Shashwat Yatishkumar Shah (Director)
Director appointed
Chandrika Joshi (Director)
10

Key Observations

Auto-generated from the data above
Debt-to-equity stands at 0.86 - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
10 active director(s) / partner(s); review board churn before relying on management continuity.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Steris Healthcare Private Limited U74999RJ2018PTC061186 Jaipur, Rajasthan, India
Nishant Aromas U74999MH2019PTC326261 Mumbai, Maharashtra, India
Celebrity Biopharma Limited U24230HP2005PLC028852 Himachal Pradesh, Himachal Pradesh, India
Africure U24303MH2017PTC291491 Palghar, Maharashtra, India
Aadi Chemtrade Limited U70100MH1986PLC041350 Mumbai, Maharashtra, India
Daxin Pharmaceuticals Private Limited U24100DL2014PTC264559 New Delhi, Delhi, India
Vamso Biotec Private Limited U74899DL2005PTC141118 New Delhi, Delhi, India
Gynoveda U21002MH2019PTC327679 Malad West, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Claroid Pharmaceuticals before audits and certifications: compliance score 83/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Claroid Pharmaceuticals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 75/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Claroid Pharmaceuticals - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 77/100, distress signals and MSME payment-delay disclosures - know whether Claroid Pharmaceuticals pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Claroid Pharmaceuticals - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Claroid Pharmaceuticals an active company?

Claroid Pharmaceuticals has MCA status “Active” with a compliance score of 83/100 (Low Risk).

Is Claroid Pharmaceuticals financially healthy?

Claroid Pharmaceuticals has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.

Should I do business with Claroid Pharmaceuticals?

Its overall Trust Score is 77/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Claroid Pharmaceuticals?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 10 active director(s) are on record.

Does Claroid Pharmaceuticals have loans or charges against its assets?

1 open charge(s) are registered against its assets.

Is Claroid Pharmaceuticals up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 83/100 (Low Risk).

Is it risky to lend to Claroid Pharmaceuticals?

Its Credit Risk Score is 75/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.